KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Interest Expenses (2023 - 2025)

Travere Therapeutics (TVTX) has disclosed Interest Expenses for 7 consecutive years, with $2.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Interest Expenses fell 24.02% year-over-year to $2.2 million, compared with a TTM value of $10.7 million through Dec 2025, down 4.46%, and an annual FY2025 reading of $10.7 million, down 4.46% over the prior year.
  • Interest Expenses was $2.2 million for Q4 2025 at Travere Therapeutics, down from $2.8 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $2.9 million in Q1 2025 and bottomed at $2.2 million in Q4 2025.
  • Average Interest Expenses over 3 years is $2.8 million, with a median of $2.8 million recorded in 2023.
  • Peak annual rise in Interest Expenses hit 3.57% in 2025, while the deepest fall reached 24.02% in 2025.
  • Year by year, Interest Expenses stood at $2.8 million in 2023, then increased by 1.25% to $2.8 million in 2024, then decreased by 24.02% to $2.2 million in 2025.
  • Business Quant data shows Interest Expenses for TVTX at $2.2 million in Q4 2025, $2.8 million in Q3 2025, and $2.8 million in Q2 2025.